�ݺ�ߣshows by User: AmrHasanNeuro

�ݺ�ߣshows by User: AmrHasanNeuro / http://www.slideshare.net/images/logo.gif �ݺ�ߣshows by User: AmrHasanNeuro / Wed, 10 May 2023 19:11:57 GMT �ݺ�ߣShare feed for �ݺ�ߣshows by User: AmrHasanNeuro Parkinson disease.pdf /slideshow/parkinson-diseasepdf/257770201 parkinsondisease-230510191157-415c86aa
Parkinsonism is a clinical syndrome and, typically, when the condition appears to be idiopathic and responsive to levodopa therapy, is referred to as Parkinson’s disease1 • The four cardinal features of the parkinsonian syndrome are:2 – Bradykinesia – Muscular rigidity – Resting tremor – Postural instability (and gait impairment) • These features are not always observed in every patient, at any given time To make a diagnosis of PD, the physician must distinguish between different forms of parkinsonism:1 – Parkinson’s disease – Secondary parkinsonism – Parkinsonism as part of another neurodegenerative disorder (e.g., multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, or Lewy body dementia) SCALES COMMONLY USED IN PARKINSON’S DISEASE RESEARCH SCALES COMMONLY USED IN PARKINSON’S DISEASE RESEARCH]]>
Parkinsonism is a clinical syndrome and, typically, when the condition appears to be idiopathic and responsive to levodopa therapy, is referred to as Parkinson’s disease1 • The four cardinal features of the parkinsonian syndrome are:2 – Bradykinesia – Muscular rigidity – Resting tremor – Postural instability (and gait impairment) • These features are not always observed in every patient, at any given time To make a diagnosis of PD, the physician must distinguish between different forms of parkinsonism:1 – Parkinson’s disease – Secondary parkinsonism – Parkinsonism as part of another neurodegenerative disorder (e.g., multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, or Lewy body dementia) SCALES COMMONLY USED IN PARKINSON’S DISEASE RESEARCH SCALES COMMONLY USED IN PARKINSON’S DISEASE RESEARCH]]> Wed, 10 May 2023 19:11:57 GMT /slideshow/parkinson-diseasepdf/257770201 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Parkinson disease.pdf AmrHasanNeuro Parkinsonism is a clinical syndrome and, typically, when the condition appears to be idiopathic and responsive to levodopa therapy, is referred to as Parkinson’s disease1 • The four cardinal features of the parkinsonian syndrome are:2 – Bradykinesia – Muscular rigidity – Resting tremor – Postural instability (and gait impairment) • These features are not always observed in every patient, at any given time To make a diagnosis of PD, the physician must distinguish between different forms of parkinsonism:1 – Parkinson’s disease – Secondary parkinsonism – Parkinsonism as part of another neurodegenerative disorder (e.g., multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, or Lewy body dementia) SCALES COMMONLY USED IN PARKINSON’S DISEASE RESEARCH SCALES COMMONLY USED IN PARKINSON’S DISEASE RESEARCH <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/parkinsondisease-230510191157-415c86aa-thumbnail.jpg?width=120&height=120&fit=bounds" /> Parkinsonism is a clinical syndrome and, typically, when the condition appears to be idiopathic and responsive to levodopa therapy, is referred to as Parkinson’s disease1 • The four cardinal features of the parkinsonian syndrome are:2 – Bradykinesia – Muscular rigidity – Resting tremor – Postural instability (and gait impairment) • These features are not always observed in every patient, at any given time To make a diagnosis of PD, the physician must distinguish between different forms of parkinsonism:1 – Parkinson’s disease – Secondary parkinsonism – Parkinsonism as part of another neurodegenerative disorder (e.g., multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, or Lewy body dementia) SCALES COMMONLY USED IN PARKINSON’S DISEASE RESEARCH SCALES COMMONLY USED IN PARKINSON’S DISEASE RESEARCH

Parkinson disease.pdf from Amr Hassan

]]> 4580 0 https://cdn.slidesharecdn.com/ss_thumbnails/parkinsondisease-230510191157-415c86aa-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Progressive multifocal leukoencephalopathy (PML) /slideshow/progressive-multifocal-leukoencephalopathy-pml/251649798 pml-220423195132
Progressive multifocal leukoencephalopathy (PML) is a disease of the white matter of the brain, caused by a virus infection that targets cells that make myelin--the material that insulates nerve cells (neurons). Polyomavirus JC (often called JC virus) is carried by a majority of people and is harmless except among those with lowered immune defenses. The disease is rare and occurs in patients undergoing chronic corticosteroid or immunosuppressive therapy for organ transplant, or individuals with cancer (such as Hodgkin’s disease or lymphoma). Individuals with autoimmune conditions such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus -- some of whom are treated with biological therapies that allow JC virus reactivation -- are at risk for PML as well. PML is most common among individuals with HIV-1 infection / acquired immune deficiency syndrome (AIDS). Currently, the best available therapy is reversal of the immune-deficient state, since there are no effective drugs that block virus infection without toxicity. Reversal may be achieved by using plasma exchange to accelerate the removal of the therapeutic agents that put patients at risk for PML. In the case of HIV-associated PML, immediately beginning anti-retroviral therapy will benefit most individuals. Several new drugs that laboratory tests found effective against infection are being used in PML patients with special permission of the U.S. Food and Drug Administration. Hexadecyloxypropyl-Cidofovir (CMX001) is currently being studied as a treatment option for JVC because of its ability to suppress JVC by inhibiting viral DNA replication. In general, PML has a mortality rate of 30-50 percent in the first few months following diagnosis but depends on the severity of the underlying disease and treatment received. Those who survive PML can be left with severe neurological disabilities. ]]>
Progressive multifocal leukoencephalopathy (PML) is a disease of the white matter of the brain, caused by a virus infection that targets cells that make myelin--the material that insulates nerve cells (neurons). Polyomavirus JC (often called JC virus) is carried by a majority of people and is harmless except among those with lowered immune defenses. The disease is rare and occurs in patients undergoing chronic corticosteroid or immunosuppressive therapy for organ transplant, or individuals with cancer (such as Hodgkin’s disease or lymphoma). Individuals with autoimmune conditions such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus -- some of whom are treated with biological therapies that allow JC virus reactivation -- are at risk for PML as well. PML is most common among individuals with HIV-1 infection / acquired immune deficiency syndrome (AIDS). Currently, the best available therapy is reversal of the immune-deficient state, since there are no effective drugs that block virus infection without toxicity. Reversal may be achieved by using plasma exchange to accelerate the removal of the therapeutic agents that put patients at risk for PML. In the case of HIV-associated PML, immediately beginning anti-retroviral therapy will benefit most individuals. Several new drugs that laboratory tests found effective against infection are being used in PML patients with special permission of the U.S. Food and Drug Administration. Hexadecyloxypropyl-Cidofovir (CMX001) is currently being studied as a treatment option for JVC because of its ability to suppress JVC by inhibiting viral DNA replication. In general, PML has a mortality rate of 30-50 percent in the first few months following diagnosis but depends on the severity of the underlying disease and treatment received. Those who survive PML can be left with severe neurological disabilities. ]]> Sat, 23 Apr 2022 19:51:31 GMT /slideshow/progressive-multifocal-leukoencephalopathy-pml/251649798 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Progressive multifocal leukoencephalopathy (PML) AmrHasanNeuro Progressive multifocal leukoencephalopathy (PML) is a disease of the white matter of the brain, caused by a virus infection that targets cells that make myelin--the material that insulates nerve cells (neurons). Polyomavirus JC (often called JC virus) is carried by a majority of people and is harmless except among those with lowered immune defenses. The disease is rare and occurs in patients undergoing chronic corticosteroid or immunosuppressive therapy for organ transplant, or individuals with cancer (such as Hodgkin’s disease or lymphoma). Individuals with autoimmune conditions such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus -- some of whom are treated with biological therapies that allow JC virus reactivation -- are at risk for PML as well. PML is most common among individuals with HIV-1 infection / acquired immune deficiency syndrome (AIDS). Currently, the best available therapy is reversal of the immune-deficient state, since there are no effective drugs that block virus infection without toxicity. Reversal may be achieved by using plasma exchange to accelerate the removal of the therapeutic agents that put patients at risk for PML. In the case of HIV-associated PML, immediately beginning anti-retroviral therapy will benefit most individuals. Several new drugs that laboratory tests found effective against infection are being used in PML patients with special permission of the U.S. Food and Drug Administration. Hexadecyloxypropyl-Cidofovir (CMX001) is currently being studied as a treatment option for JVC because of its ability to suppress JVC by inhibiting viral DNA replication. In general, PML has a mortality rate of 30-50 percent in the first few months following diagnosis but depends on the severity of the underlying disease and treatment received. Those who survive PML can be left with severe neurological disabilities. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/pml-220423195132-thumbnail.jpg?width=120&height=120&fit=bounds" /> Progressive multifocal leukoencephalopathy (PML) is a disease of the white matter of the brain, caused by a virus infection that targets cells that make myelin--the material that insulates nerve cells (neurons). Polyomavirus JC (often called JC virus) is carried by a majority of people and is harmless except among those with lowered immune defenses. The disease is rare and occurs in patients undergoing chronic corticosteroid or immunosuppressive therapy for organ transplant, or individuals with cancer (such as Hodgkin’s disease or lymphoma). Individuals with autoimmune conditions such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus -- some of whom are treated with biological therapies that allow JC virus reactivation -- are at risk for PML as well. PML is most common among individuals with HIV-1 infection / acquired immune deficiency syndrome (AIDS). Currently, the best available therapy is reversal of the immune-deficient state, since there are no effective drugs that block virus infection without toxicity. Reversal may be achieved by using plasma exchange to accelerate the removal of the therapeutic agents that put patients at risk for PML. In the case of HIV-associated PML, immediately beginning anti-retroviral therapy will benefit most individuals. Several new drugs that laboratory tests found effective against infection are being used in PML patients with special permission of the U.S. Food and Drug Administration. Hexadecyloxypropyl-Cidofovir (CMX001) is currently being studied as a treatment option for JVC because of its ability to suppress JVC by inhibiting viral DNA replication. In general, PML has a mortality rate of 30-50 percent in the first few months following diagnosis but depends on the severity of the underlying disease and treatment received. Those who survive PML can be left with severe neurological disabilities.

Progressive multifocal leukoencephalopathy (PML) from Amr Hassan

]]> 2755 0 https://cdn.slidesharecdn.com/ss_thumbnails/pml-220423195132-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Sequencing in management of Multiple sclerosis /slideshow/sequencing-in-management-of-multiple-sclerosis/251644506 sequencingdramrhassanlongmerck-220422193931
Sequencing of DMTs for individual multiple sclerosis patients should be designed in such a way to maximize disease control and minimize risk based on the mechanism of action, pharmacokinetic and pharmacodynamic properties of each therapy. This includes the DMT patients are being switched from to those they are being switched to. The reversibility of immune system effects should be a key consideration for DMT sequence selection. This feature varies across DMTs and should factor more prominently in decision making as newer treatments become available for the prevention of disability accumulation in patients with progressive MS. In this short review, we discuss the landscape of existing therapies with an eye to the future when planning for optimal DMT sequencing. While no cure exists for MS, efforts are being directed toward research in neuroregeneration with the hope for positive outcomes. ]]>
Sequencing of DMTs for individual multiple sclerosis patients should be designed in such a way to maximize disease control and minimize risk based on the mechanism of action, pharmacokinetic and pharmacodynamic properties of each therapy. This includes the DMT patients are being switched from to those they are being switched to. The reversibility of immune system effects should be a key consideration for DMT sequence selection. This feature varies across DMTs and should factor more prominently in decision making as newer treatments become available for the prevention of disability accumulation in patients with progressive MS. In this short review, we discuss the landscape of existing therapies with an eye to the future when planning for optimal DMT sequencing. While no cure exists for MS, efforts are being directed toward research in neuroregeneration with the hope for positive outcomes. ]]> Fri, 22 Apr 2022 19:39:30 GMT /slideshow/sequencing-in-management-of-multiple-sclerosis/251644506 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Sequencing in management of Multiple sclerosis AmrHasanNeuro Sequencing of DMTs for individual multiple sclerosis patients should be designed in such a way to maximize disease control and minimize risk based on the mechanism of action, pharmacokinetic and pharmacodynamic properties of each therapy. This includes the DMT patients are being switched from to those they are being switched to. The reversibility of immune system effects should be a key consideration for DMT sequence selection. This feature varies across DMTs and should factor more prominently in decision making as newer treatments become available for the prevention of disability accumulation in patients with progressive MS. In this short review, we discuss the landscape of existing therapies with an eye to the future when planning for optimal DMT sequencing. While no cure exists for MS, efforts are being directed toward research in neuroregeneration with the hope for positive outcomes. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/sequencingdramrhassanlongmerck-220422193931-thumbnail.jpg?width=120&height=120&fit=bounds" /> Sequencing of DMTs for individual multiple sclerosis patients should be designed in such a way to maximize disease control and minimize risk based on the mechanism of action, pharmacokinetic and pharmacodynamic properties of each therapy. This includes the DMT patients are being switched from to those they are being switched to. The reversibility of immune system effects should be a key consideration for DMT sequence selection. This feature varies across DMTs and should factor more prominently in decision making as newer treatments become available for the prevention of disability accumulation in patients with progressive MS. In this short review, we discuss the landscape of existing therapies with an eye to the future when planning for optimal DMT sequencing. While no cure exists for MS, efforts are being directed toward research in neuroregeneration with the hope for positive outcomes.

Sequencing in management of Multiple sclerosis from Amr Hassan

]]> 917 0 https://cdn.slidesharecdn.com/ss_thumbnails/sequencingdramrhassanlongmerck-220422193931-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Myathenia Gravis /slideshow/myathenia-gravis/251636157 mg-220421202935
A neuromuscular disorder that leads to weakness of skeletal muscles. Symptoms Causes Prevention Complications Common tests & procedures Neurological examination: Repetitive nerve stimulation test: Antibody test: Pulmonary function tests (PFTs): To check any breathing difficulty. CT scan: To rule out a presence of tumor in thymus. Magnetic resonance imaging (MRI): MRI of the chest is performed to rule out a presence of tumor in thymus. Edrophonium (Tensilon) test: Medication Procedures Nutrition]]>
A neuromuscular disorder that leads to weakness of skeletal muscles. Symptoms Causes Prevention Complications Common tests & procedures Neurological examination: Repetitive nerve stimulation test: Antibody test: Pulmonary function tests (PFTs): To check any breathing difficulty. CT scan: To rule out a presence of tumor in thymus. Magnetic resonance imaging (MRI): MRI of the chest is performed to rule out a presence of tumor in thymus. Edrophonium (Tensilon) test: Medication Procedures Nutrition]]> Thu, 21 Apr 2022 20:29:35 GMT /slideshow/myathenia-gravis/251636157 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Myathenia Gravis AmrHasanNeuro A neuromuscular disorder that leads to weakness of skeletal muscles. Symptoms Causes Prevention Complications Common tests & procedures Neurological examination: Repetitive nerve stimulation test: Antibody test: Pulmonary function tests (PFTs): To check any breathing difficulty. CT scan: To rule out a presence of tumor in thymus. Magnetic resonance imaging (MRI): MRI of the chest is performed to rule out a presence of tumor in thymus. Edrophonium (Tensilon) test: Medication Procedures Nutrition <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/mg-220421202935-thumbnail.jpg?width=120&height=120&fit=bounds" /> A neuromuscular disorder that leads to weakness of skeletal muscles. Symptoms Causes Prevention Complications Common tests & procedures Neurological examination: Repetitive nerve stimulation test: Antibody test: Pulmonary function tests (PFTs): To check any breathing difficulty. CT scan: To rule out a presence of tumor in thymus. Magnetic resonance imaging (MRI): MRI of the chest is performed to rule out a presence of tumor in thymus. Edrophonium (Tensilon) test: Medication Procedures Nutrition

Myathenia Gravis from Amr Hassan

]]> 1002 0 https://cdn.slidesharecdn.com/ss_thumbnails/mg-220421202935-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Prediction of outcome of Multiple sclerosis /slideshow/prediction-of-outcome-of-multiple-sclerosis/248258225 predictionofoutcomeofms-210510225014
Prediction of outcome of Multiple sclerosis An understanding of the natural history of multiple sclerosis(MS) in a patient is important to begin proper treatment at the correct time, especially when there is a high risk for poor prognosis. Factors that predict unfavorable prognosis are a primary or secondary progressive course, older age at disease onset, short interval between first and second attacks, initial cerebellar or pyramidal symptoms, a large number of functional systems involved at onset, moderate to severe disability within the first 2 years, and the presence of typical plaques or greater lesion volume shown by magnetic resonance imaging results during the first 5 years. However, there are no established laboratory tests able to predict long-term prognosis. ]]>
Prediction of outcome of Multiple sclerosis An understanding of the natural history of multiple sclerosis(MS) in a patient is important to begin proper treatment at the correct time, especially when there is a high risk for poor prognosis. Factors that predict unfavorable prognosis are a primary or secondary progressive course, older age at disease onset, short interval between first and second attacks, initial cerebellar or pyramidal symptoms, a large number of functional systems involved at onset, moderate to severe disability within the first 2 years, and the presence of typical plaques or greater lesion volume shown by magnetic resonance imaging results during the first 5 years. However, there are no established laboratory tests able to predict long-term prognosis. ]]> Mon, 10 May 2021 22:50:14 GMT /slideshow/prediction-of-outcome-of-multiple-sclerosis/248258225 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Prediction of outcome of Multiple sclerosis AmrHasanNeuro Prediction of outcome of Multiple sclerosis An understanding of the natural history of multiple sclerosis(MS) in a patient is important to begin proper treatment at the correct time, especially when there is a high risk for poor prognosis. Factors that predict unfavorable prognosis are a primary or secondary progressive course, older age at disease onset, short interval between first and second attacks, initial cerebellar or pyramidal symptoms, a large number of functional systems involved at onset, moderate to severe disability within the first 2 years, and the presence of typical plaques or greater lesion volume shown by magnetic resonance imaging results during the first 5 years. However, there are no established laboratory tests able to predict long-term prognosis. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/predictionofoutcomeofms-210510225014-thumbnail.jpg?width=120&height=120&fit=bounds" /> Prediction of outcome of Multiple sclerosis An understanding of the natural history of multiple sclerosis(MS) in a patient is important to begin proper treatment at the correct time, especially when there is a high risk for poor prognosis. Factors that predict unfavorable prognosis are a primary or secondary progressive course, older age at disease onset, short interval between first and second attacks, initial cerebellar or pyramidal symptoms, a large number of functional systems involved at onset, moderate to severe disability within the first 2 years, and the presence of typical plaques or greater lesion volume shown by magnetic resonance imaging results during the first 5 years. However, there are no established laboratory tests able to predict long-term prognosis.

Prediction of outcome of Multiple sclerosis from Amr Hassan

]]> 1698 0 https://cdn.slidesharecdn.com/ss_thumbnails/predictionofoutcomeofms-210510225014-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Lifestyle modification in epilepsy /slideshow/lifestyle-modification-in-epilepsy/248258163 lifestylemodificationinepilepsy-210510224825
Lifestyle modification in epilepsy Lifestyle Modifications Lifestyle modifications can include: Adequate sleep: Fatigue is one of the most common seizure triggers, and disrupted sleep can make the brain more vulnerable to misfiring. Avoiding drugs and alcohol: These can be triggers for seizures in patients with epilepsy. Even one or two drinks can provoke seizures. Minimizing emotional stress: Although there is not definitive proof that stress causes seizures, those who maintain healthy stress levels have reported that they believe it reduces their risk. Frequency of exercise: In addition to a range of health benefits, regular exercise can help reduce risk of seizure. However, you should consult your physician before starting a new exercise routine, as some exercise can, rarely, cause seizures. ]]>
Lifestyle modification in epilepsy Lifestyle Modifications Lifestyle modifications can include: Adequate sleep: Fatigue is one of the most common seizure triggers, and disrupted sleep can make the brain more vulnerable to misfiring. Avoiding drugs and alcohol: These can be triggers for seizures in patients with epilepsy. Even one or two drinks can provoke seizures. Minimizing emotional stress: Although there is not definitive proof that stress causes seizures, those who maintain healthy stress levels have reported that they believe it reduces their risk. Frequency of exercise: In addition to a range of health benefits, regular exercise can help reduce risk of seizure. However, you should consult your physician before starting a new exercise routine, as some exercise can, rarely, cause seizures. ]]> Mon, 10 May 2021 22:48:24 GMT /slideshow/lifestyle-modification-in-epilepsy/248258163 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Lifestyle modification in epilepsy AmrHasanNeuro Lifestyle modification in epilepsy Lifestyle Modifications Lifestyle modifications can include: Adequate sleep: Fatigue is one of the most common seizure triggers, and disrupted sleep can make the brain more vulnerable to misfiring. Avoiding drugs and alcohol: These can be triggers for seizures in patients with epilepsy. Even one or two drinks can provoke seizures. Minimizing emotional stress: Although there is not definitive proof that stress causes seizures, those who maintain healthy stress levels have reported that they believe it reduces their risk. Frequency of exercise: In addition to a range of health benefits, regular exercise can help reduce risk of seizure. However, you should consult your physician before starting a new exercise routine, as some exercise can, rarely, cause seizures. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/lifestylemodificationinepilepsy-210510224825-thumbnail.jpg?width=120&height=120&fit=bounds" /> Lifestyle modification in epilepsy Lifestyle Modifications Lifestyle modifications can include: Adequate sleep: Fatigue is one of the most common seizure triggers, and disrupted sleep can make the brain more vulnerable to misfiring. Avoiding drugs and alcohol: These can be triggers for seizures in patients with epilepsy. Even one or two drinks can provoke seizures. Minimizing emotional stress: Although there is not definitive proof that stress causes seizures, those who maintain healthy stress levels have reported that they believe it reduces their risk. Frequency of exercise: In addition to a range of health benefits, regular exercise can help reduce risk of seizure. However, you should consult your physician before starting a new exercise routine, as some exercise can, rarely, cause seizures.

Lifestyle modification in epilepsy from Amr Hassan

]]> 1182 0 https://cdn.slidesharecdn.com/ss_thumbnails/lifestylemodificationinepilepsy-210510224825-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Childhood demyelinating syndromes /AmrHasanNeuro/childhood-demyelinating-syndromes childhooddemyelinatingsyndrome-210510224441
Childhood demyelinating syndromes In the past decade, the number of studies related to demyelinating diseases in children has exponentially increased. Demyelinating disease in children may be monophasic or chronic. Typical monophasic disorders in children are acute disseminated encephalomyelitis and clinically isolated syndromes, including optic neuritis and transverse myelitis. However, some cases of acute disseminated encephalomyelitis or clinically isolated syndrome progress to become chronic disorders, including multiple sclerosis and neuromyelitis optica. This review summarizes the current knowledge on monophasic and chronic demyelinating disorders in children, focusing on an approach to diagnosis and management. ]]>
Childhood demyelinating syndromes In the past decade, the number of studies related to demyelinating diseases in children has exponentially increased. Demyelinating disease in children may be monophasic or chronic. Typical monophasic disorders in children are acute disseminated encephalomyelitis and clinically isolated syndromes, including optic neuritis and transverse myelitis. However, some cases of acute disseminated encephalomyelitis or clinically isolated syndrome progress to become chronic disorders, including multiple sclerosis and neuromyelitis optica. This review summarizes the current knowledge on monophasic and chronic demyelinating disorders in children, focusing on an approach to diagnosis and management. ]]> Mon, 10 May 2021 22:44:41 GMT /AmrHasanNeuro/childhood-demyelinating-syndromes AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Childhood demyelinating syndromes AmrHasanNeuro Childhood demyelinating syndromes In the past decade, the number of studies related to demyelinating diseases in children has exponentially increased. Demyelinating disease in children may be monophasic or chronic. Typical monophasic disorders in children are acute disseminated encephalomyelitis and clinically isolated syndromes, including optic neuritis and transverse myelitis. However, some cases of acute disseminated encephalomyelitis or clinically isolated syndrome progress to become chronic disorders, including multiple sclerosis and neuromyelitis optica. This review summarizes the current knowledge on monophasic and chronic demyelinating disorders in children, focusing on an approach to diagnosis and management. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/childhooddemyelinatingsyndrome-210510224441-thumbnail.jpg?width=120&height=120&fit=bounds" /> Childhood demyelinating syndromes In the past decade, the number of studies related to demyelinating diseases in children has exponentially increased. Demyelinating disease in children may be monophasic or chronic. Typical monophasic disorders in children are acute disseminated encephalomyelitis and clinically isolated syndromes, including optic neuritis and transverse myelitis. However, some cases of acute disseminated encephalomyelitis or clinically isolated syndrome progress to become chronic disorders, including multiple sclerosis and neuromyelitis optica. This review summarizes the current knowledge on monophasic and chronic demyelinating disorders in children, focusing on an approach to diagnosis and management.

Childhood demyelinating syndromes from Amr Hassan

]]> 1761 0 https://cdn.slidesharecdn.com/ss_thumbnails/childhooddemyelinatingsyndrome-210510224441-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Diabetic polyneuropathy /slideshow/diabetic-polyneuropathy-248129777/248129777 dpn-long-copy-210508211826
Diabetic polyneuropathy Diabetic polyneuropathy (DPN) is defined as peripheral nerve dysfunction. There are three main alterations involved in the pathologic changes of DPN: inflammation, oxidative stress, and mitochondrial dysfunction.]]>
Diabetic polyneuropathy Diabetic polyneuropathy (DPN) is defined as peripheral nerve dysfunction. There are three main alterations involved in the pathologic changes of DPN: inflammation, oxidative stress, and mitochondrial dysfunction.]]> Sat, 08 May 2021 21:18:25 GMT /slideshow/diabetic-polyneuropathy-248129777/248129777 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Diabetic polyneuropathy AmrHasanNeuro Diabetic polyneuropathy Diabetic polyneuropathy (DPN) is defined as peripheral nerve dysfunction. There are three main alterations involved in the pathologic changes of DPN: inflammation, oxidative stress, and mitochondrial dysfunction. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/dpn-long-copy-210508211826-thumbnail.jpg?width=120&height=120&fit=bounds" /> Diabetic polyneuropathy Diabetic polyneuropathy (DPN) is defined as peripheral nerve dysfunction. There are three main alterations involved in the pathologic changes of DPN: inflammation, oxidative stress, and mitochondrial dysfunction.

Diabetic polyneuropathy from Amr Hassan

]]> 2629 0 https://cdn.slidesharecdn.com/ss_thumbnails/dpn-long-copy-210508211826-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Excessive daytime sleepiness /slideshow/excessive-daytime-sleepiness-248129728/248129728 excessivedaytimesleepiness-210508211437
Excessive daytime sleepiness The most common causes of excessive daytime sleepiness are sleep deprivation, obstructive sleep apnea, and sedating medications. Other potential causes of excessive daytime sleepiness include certain medical and psychiatric conditions and sleep disorders, such as narcolepsy. ]]>
Excessive daytime sleepiness The most common causes of excessive daytime sleepiness are sleep deprivation, obstructive sleep apnea, and sedating medications. Other potential causes of excessive daytime sleepiness include certain medical and psychiatric conditions and sleep disorders, such as narcolepsy. ]]> Sat, 08 May 2021 21:14:37 GMT /slideshow/excessive-daytime-sleepiness-248129728/248129728 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Excessive daytime sleepiness AmrHasanNeuro Excessive daytime sleepiness The most common causes of excessive daytime sleepiness are sleep deprivation, obstructive sleep apnea, and sedating medications. Other potential causes of excessive daytime sleepiness include certain medical and psychiatric conditions and sleep disorders, such as narcolepsy. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/excessivedaytimesleepiness-210508211437-thumbnail.jpg?width=120&height=120&fit=bounds" /> Excessive daytime sleepiness The most common causes of excessive daytime sleepiness are sleep deprivation, obstructive sleep apnea, and sedating medications. Other potential causes of excessive daytime sleepiness include certain medical and psychiatric conditions and sleep disorders, such as narcolepsy.

Excessive daytime sleepiness from Amr Hassan

]]> 941 0 https://cdn.slidesharecdn.com/ss_thumbnails/excessivedaytimesleepiness-210508211437-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Vagal Nerve stimulation /slideshow/vagal-nerve-stimulation-248129567/248129567 vnslong-210508210155
Vagal Nerve stimulation Vagus nerve stimulation (VNS) is a medical treatment that involves delivering electrical impulses to the vagus nerve. It is used as an add-on treatment for certain types of intractable epilepsy and treatment-resistant depression. Frequent side effects include coughing and shortness of breath. Serious side effects may include trouble talking and cardiac arrest.]]>
Vagal Nerve stimulation Vagus nerve stimulation (VNS) is a medical treatment that involves delivering electrical impulses to the vagus nerve. It is used as an add-on treatment for certain types of intractable epilepsy and treatment-resistant depression. Frequent side effects include coughing and shortness of breath. Serious side effects may include trouble talking and cardiac arrest.]]> Sat, 08 May 2021 21:01:55 GMT /slideshow/vagal-nerve-stimulation-248129567/248129567 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Vagal Nerve stimulation AmrHasanNeuro Vagal Nerve stimulation Vagus nerve stimulation (VNS) is a medical treatment that involves delivering electrical impulses to the vagus nerve. It is used as an add-on treatment for certain types of intractable epilepsy and treatment-resistant depression. Frequent side effects include coughing and shortness of breath. Serious side effects may include trouble talking and cardiac arrest. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/vnslong-210508210155-thumbnail.jpg?width=120&height=120&fit=bounds" /> Vagal Nerve stimulation Vagus nerve stimulation (VNS) is a medical treatment that involves delivering electrical impulses to the vagus nerve. It is used as an add-on treatment for certain types of intractable epilepsy and treatment-resistant depression. Frequent side effects include coughing and shortness of breath. Serious side effects may include trouble talking and cardiac arrest.

Vagal Nerve stimulation from Amr Hassan

]]> 3082 0 https://cdn.slidesharecdn.com/ss_thumbnails/vnslong-210508210155-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Dystonia /slideshow/dystonia-247937854/247937854 dystonia-210506204950
Dystonia Dystonia is a movement disorder in which your muscles contract involuntarily, causing repetitive or twisting movements. The condition can affect one part of your body (focal dystonia), two or more adjacent parts (segmental dystonia) or all parts of your body (general dystonia). The muscle spasms can range from mild to severe. They may be painful, and they can interfere with your performance of day-to-day tasks. Dystonia: Causes, Types, Symptoms, and Treatments ]]>
Dystonia Dystonia is a movement disorder in which your muscles contract involuntarily, causing repetitive or twisting movements. The condition can affect one part of your body (focal dystonia), two or more adjacent parts (segmental dystonia) or all parts of your body (general dystonia). The muscle spasms can range from mild to severe. They may be painful, and they can interfere with your performance of day-to-day tasks. Dystonia: Causes, Types, Symptoms, and Treatments ]]> Thu, 06 May 2021 20:49:49 GMT /slideshow/dystonia-247937854/247937854 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Dystonia AmrHasanNeuro Dystonia Dystonia is a movement disorder in which your muscles contract involuntarily, causing repetitive or twisting movements. The condition can affect one part of your body (focal dystonia), two or more adjacent parts (segmental dystonia) or all parts of your body (general dystonia). The muscle spasms can range from mild to severe. They may be painful, and they can interfere with your performance of day-to-day tasks. Dystonia: Causes, Types, Symptoms, and Treatments <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/dystonia-210506204950-thumbnail.jpg?width=120&height=120&fit=bounds" /> Dystonia Dystonia is a movement disorder in which your muscles contract involuntarily, causing repetitive or twisting movements. The condition can affect one part of your body (focal dystonia), two or more adjacent parts (segmental dystonia) or all parts of your body (general dystonia). The muscle spasms can range from mild to severe. They may be painful, and they can interfere with your performance of day-to-day tasks. Dystonia: Causes, Types, Symptoms, and Treatments

Dystonia from Amr Hassan

]]> 2161 0 https://cdn.slidesharecdn.com/ss_thumbnails/dystonia-210506204950-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Trigeminal neuralgia /slideshow/trigeminal-neuralgia-247937791/247937791 tn-210506204605
Trigeminal neuralgia is sudden, severe facial pain. It's often described as a sharp shooting pain or like having an electric shock in the jaw, teeth or gums. Trigeminal neuralgia Contents Overview Symptoms Causes Diagnosis Treatment ]]>
Trigeminal neuralgia is sudden, severe facial pain. It's often described as a sharp shooting pain or like having an electric shock in the jaw, teeth or gums. Trigeminal neuralgia Contents Overview Symptoms Causes Diagnosis Treatment ]]> Thu, 06 May 2021 20:46:05 GMT /slideshow/trigeminal-neuralgia-247937791/247937791 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Trigeminal neuralgia AmrHasanNeuro Trigeminal neuralgia is sudden, severe facial pain. It's often described as a sharp shooting pain or like having an electric shock in the jaw, teeth or gums. Trigeminal neuralgia Contents Overview Symptoms Causes Diagnosis Treatment <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/tn-210506204605-thumbnail.jpg?width=120&height=120&fit=bounds" /> Trigeminal neuralgia is sudden, severe facial pain. It's often described as a sharp shooting pain or like having an electric shock in the jaw, teeth or gums. Trigeminal neuralgia Contents Overview Symptoms Causes Diagnosis Treatment

Trigeminal neuralgia from Amr Hassan

]]> 1195 0 https://cdn.slidesharecdn.com/ss_thumbnails/tn-210506204605-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Brain stimulants /slideshow/brain-stimulants/247937718 nootrpoics-210506204152
Nootropics and smart drugs are natural or synthetic substances that can be taken to improve mental performance in healthy people. They have gained popularity in today’s highly competitive society and are most often used to boost memory, focus, creativity, intelligence and motivation. Here’s a look at the ]best nootropics and how they enhance performance.]]>
Nootropics and smart drugs are natural or synthetic substances that can be taken to improve mental performance in healthy people. They have gained popularity in today’s highly competitive society and are most often used to boost memory, focus, creativity, intelligence and motivation. Here’s a look at the ]best nootropics and how they enhance performance.]]> Thu, 06 May 2021 20:41:52 GMT /slideshow/brain-stimulants/247937718 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Brain stimulants AmrHasanNeuro Nootropics and smart drugs are natural or synthetic substances that can be taken to improve mental performance in healthy people. They have gained popularity in today’s highly competitive society and are most often used to boost memory, focus, creativity, intelligence and motivation. Here’s a look at the ]best nootropics and how they enhance performance. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/nootrpoics-210506204152-thumbnail.jpg?width=120&height=120&fit=bounds" /> Nootropics and smart drugs are natural or synthetic substances that can be taken to improve mental performance in healthy people. They have gained popularity in today’s highly competitive society and are most often used to boost memory, focus, creativity, intelligence and motivation. Here’s a look at the ]best nootropics and how they enhance performance.

Brain stimulants from Amr Hassan

]]> 1197 0 https://cdn.slidesharecdn.com/ss_thumbnails/nootrpoics-210506204152-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Nystagmus /slideshow/nystagmus-247730534/247730534 nystagmus-210504204043
Nystagmus is a condition of involuntary (or voluntary, in some cases)eye movement, acquired in infancy or later in life, that in extremely rare cases may result in reduced or limited vision. Due to the involuntary movement of the eye, it has been called "dancing eyes"Contents 1 Causes 1.1 Early-onset nystagmus 1.2 Acquired nystagmus 1.3 Other causes 2 Diagnosis 2.1 Pathologic nystagmus 2.2 Physiological nystagmus 3 Treatment 4 Epidemiology]]>
Nystagmus is a condition of involuntary (or voluntary, in some cases)eye movement, acquired in infancy or later in life, that in extremely rare cases may result in reduced or limited vision. Due to the involuntary movement of the eye, it has been called "dancing eyes"Contents 1 Causes 1.1 Early-onset nystagmus 1.2 Acquired nystagmus 1.3 Other causes 2 Diagnosis 2.1 Pathologic nystagmus 2.2 Physiological nystagmus 3 Treatment 4 Epidemiology]]> Tue, 04 May 2021 20:40:43 GMT /slideshow/nystagmus-247730534/247730534 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Nystagmus AmrHasanNeuro Nystagmus is a condition of involuntary (or voluntary, in some cases)eye movement, acquired in infancy or later in life, that in extremely rare cases may result in reduced or limited vision. Due to the involuntary movement of the eye, it has been called "dancing eyes"Contents 1 Causes 1.1 Early-onset nystagmus 1.2 Acquired nystagmus 1.3 Other causes 2 Diagnosis 2.1 Pathologic nystagmus 2.2 Physiological nystagmus 3 Treatment 4 Epidemiology <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/nystagmus-210504204043-thumbnail.jpg?width=120&height=120&fit=bounds" /> Nystagmus is a condition of involuntary (or voluntary, in some cases)eye movement, acquired in infancy or later in life, that in extremely rare cases may result in reduced or limited vision. Due to the involuntary movement of the eye, it has been called "dancing eyes"Contents 1 Causes 1.1 Early-onset nystagmus 1.2 Acquired nystagmus 1.3 Other causes 2 Diagnosis 2.1 Pathologic nystagmus 2.2 Physiological nystagmus 3 Treatment 4 Epidemiology

Nystagmus from Amr Hassan

]]> 2762 0 https://cdn.slidesharecdn.com/ss_thumbnails/nystagmus-210504204043-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Basics of Neuroradiology /slideshow/basics-of-neuroradiology/247730435 neuroradiologydramrhasan-210504203514
Basics of Neuroradiology Neuroradiology is an essential tool in management of patients with neurological and neurosurgical disorders. The aim of this presentation will be to acquaint the reader to understand how images are formed on a computed tomography (CT) and magnetic resonance imaging (MRI) along with a review of the relevant neuroanatomy. This understanding will be helpful to the reader in interpretation of images and diagnosis of various neurological disorders.]]>
Basics of Neuroradiology Neuroradiology is an essential tool in management of patients with neurological and neurosurgical disorders. The aim of this presentation will be to acquaint the reader to understand how images are formed on a computed tomography (CT) and magnetic resonance imaging (MRI) along with a review of the relevant neuroanatomy. This understanding will be helpful to the reader in interpretation of images and diagnosis of various neurological disorders.]]> Tue, 04 May 2021 20:35:14 GMT /slideshow/basics-of-neuroradiology/247730435 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Basics of Neuroradiology AmrHasanNeuro Basics of Neuroradiology Neuroradiology is an essential tool in management of patients with neurological and neurosurgical disorders. The aim of this presentation will be to acquaint the reader to understand how images are formed on a computed tomography (CT) and magnetic resonance imaging (MRI) along with a review of the relevant neuroanatomy. This understanding will be helpful to the reader in interpretation of images and diagnosis of various neurological disorders. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/neuroradiologydramrhasan-210504203514-thumbnail.jpg?width=120&height=120&fit=bounds" /> Basics of Neuroradiology Neuroradiology is an essential tool in management of patients with neurological and neurosurgical disorders. The aim of this presentation will be to acquaint the reader to understand how images are formed on a computed tomography (CT) and magnetic resonance imaging (MRI) along with a review of the relevant neuroanatomy. This understanding will be helpful to the reader in interpretation of images and diagnosis of various neurological disorders.

Basics of Neuroradiology from Amr Hassan

]]> 1568 0 https://cdn.slidesharecdn.com/ss_thumbnails/neuroradiologydramrhasan-210504203514-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Cerebral venous sinus thrombosis /slideshow/cerebral-venous-sinus-thrombosis-247730340/247730340 cvt-210504203042
Cerebral venous sinus thrombosis Cerebral venous sinus thrombosis (CVST), cerebral venous and sinus thrombosis or cerebral venous thrombosis (CVT) Cerebral venous and sinus thrombosis, (superior) sagittal sinus thrombosis, dural sinus thrombosis, intracranial venous thrombosis, cerebral thrombophlebitis Contents 1 Signs and symptoms 2 Causes 3 Diagnosis 3.1 Imaging 3.2 D-dimer 3.3 Further tests 4 Pathogenesis 5 Treatment 6 Prognosis 7 Epidemiology]]>
Cerebral venous sinus thrombosis Cerebral venous sinus thrombosis (CVST), cerebral venous and sinus thrombosis or cerebral venous thrombosis (CVT) Cerebral venous and sinus thrombosis, (superior) sagittal sinus thrombosis, dural sinus thrombosis, intracranial venous thrombosis, cerebral thrombophlebitis Contents 1 Signs and symptoms 2 Causes 3 Diagnosis 3.1 Imaging 3.2 D-dimer 3.3 Further tests 4 Pathogenesis 5 Treatment 6 Prognosis 7 Epidemiology]]> Tue, 04 May 2021 20:30:42 GMT /slideshow/cerebral-venous-sinus-thrombosis-247730340/247730340 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Cerebral venous sinus thrombosis AmrHasanNeuro Cerebral venous sinus thrombosis Cerebral venous sinus thrombosis (CVST), cerebral venous and sinus thrombosis or cerebral venous thrombosis (CVT) Cerebral venous and sinus thrombosis, (superior) sagittal sinus thrombosis, dural sinus thrombosis, intracranial venous thrombosis, cerebral thrombophlebitis Contents 1 Signs and symptoms 2 Causes 3 Diagnosis 3.1 Imaging 3.2 D-dimer 3.3 Further tests 4 Pathogenesis 5 Treatment 6 Prognosis 7 Epidemiology <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/cvt-210504203042-thumbnail.jpg?width=120&height=120&fit=bounds" /> Cerebral venous sinus thrombosis Cerebral venous sinus thrombosis (CVST), cerebral venous and sinus thrombosis or cerebral venous thrombosis (CVT) Cerebral venous and sinus thrombosis, (superior) sagittal sinus thrombosis, dural sinus thrombosis, intracranial venous thrombosis, cerebral thrombophlebitis Contents 1 Signs and symptoms 2 Causes 3 Diagnosis 3.1 Imaging 3.2 D-dimer 3.3 Further tests 4 Pathogenesis 5 Treatment 6 Prognosis 7 Epidemiology

Cerebral venous sinus thrombosis from Amr Hassan

]]> 1061 0 https://cdn.slidesharecdn.com/ss_thumbnails/cvt-210504203042-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Childhood and juvenile movement disorders /slideshow/childhood-ampjuvenile-md/126437788 childhoodjuvenilemd-181221134614
Parkinsonism Tics Tremors Chorea Ataxia Dystonias Myoclonus Childhood and Juvenile movement disorders Mixed]]>
Parkinsonism Tics Tremors Chorea Ataxia Dystonias Myoclonus Childhood and Juvenile movement disorders Mixed]]> Fri, 21 Dec 2018 13:46:14 GMT /slideshow/childhood-ampjuvenile-md/126437788 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Childhood and juvenile movement disorders AmrHasanNeuro Parkinsonism Tics Tremors Chorea Ataxia Dystonias Myoclonus Childhood and Juvenile movement disorders Mixed <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/childhoodjuvenilemd-181221134614-thumbnail.jpg?width=120&height=120&fit=bounds" /> Parkinsonism Tics Tremors Chorea Ataxia Dystonias Myoclonus Childhood and Juvenile movement disorders Mixed

Childhood and juvenile movement disorders from Amr Hassan

]]> 3845 4 https://cdn.slidesharecdn.com/ss_thumbnails/childhoodjuvenilemd-181221134614-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 New Antiepileptic drugs /slideshow/new-antiepileptic-drugs/126437660 epilepsynewpipeline-181221134352
Seizure control New Antiepileptic drugs ]]>
Seizure control New Antiepileptic drugs ]]> Fri, 21 Dec 2018 13:43:52 GMT /slideshow/new-antiepileptic-drugs/126437660 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) New Antiepileptic drugs AmrHasanNeuro Seizure control New Antiepileptic drugs <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/epilepsynewpipeline-181221134352-thumbnail.jpg?width=120&height=120&fit=bounds" /> Seizure control New Antiepileptic drugs

New Antiepileptic drugs from Amr Hassan

]]> 3637 12 https://cdn.slidesharecdn.com/ss_thumbnails/epilepsynewpipeline-181221134352-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Zonisamide /slideshow/zonisamide-126437542/126437542 zonisamide-181221134132
Zonisamide]]>
Zonisamide]]> Fri, 21 Dec 2018 13:41:32 GMT /slideshow/zonisamide-126437542/126437542 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) Zonisamide AmrHasanNeuro Zonisamide <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/zonisamide-181221134132-thumbnail.jpg?width=120&height=120&fit=bounds" /> Zonisamide

Zonisamide from Amr Hassan

]]> 1903 7 https://cdn.slidesharecdn.com/ss_thumbnails/zonisamide-181221134132-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 stem cell transplantation in pediatric neurology /slideshow/stem-cell-transplantation-in-pediatric-neurology/126437455 sctinpedneuology-181221133956
stem cell transplantation in pediatric neurology and cerebral palsy ]]>
stem cell transplantation in pediatric neurology and cerebral palsy ]]> Fri, 21 Dec 2018 13:39:56 GMT /slideshow/stem-cell-transplantation-in-pediatric-neurology/126437455 AmrHasanNeuro@slideshare.net(AmrHasanNeuro) stem cell transplantation in pediatric neurology AmrHasanNeuro stem cell transplantation in pediatric neurology and cerebral palsy <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/sctinpedneuology-181221133956-thumbnail.jpg?width=120&height=120&fit=bounds" /> stem cell transplantation in pediatric neurology and cerebral palsy

stem cell transplantation in pediatric neurology from Amr Hassan

]]> 845 5 https://cdn.slidesharecdn.com/ss_thumbnails/sctinpedneuology-181221133956-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 https://cdn.slidesharecdn.com/profile-photo-AmrHasanNeuro-48x48.jpg?cb=1724924064 Professor and Consultant of Neurology Kasr Al Ainy hospital Cairo University Cairo Egypt www.amrhasanneuro.com https://cdn.slidesharecdn.com/ss_thumbnails/parkinsondisease-230510191157-415c86aa-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/parkinson-diseasepdf/257770201 Parkinson disease.pdf https://cdn.slidesharecdn.com/ss_thumbnails/pml-220423195132-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/progressive-multifocal-leukoencephalopathy-pml/251649798 Progressive multifocal... https://cdn.slidesharecdn.com/ss_thumbnails/sequencingdramrhassanlongmerck-220422193931-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/sequencing-in-management-of-multiple-sclerosis/251644506 Sequencing in manageme...